Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype


Lakhani, SR; Reis-Filho, JS; Fulford, L; Penault-Llorca, F; van der Vjiver, M; Parry, S; Bishop, T; Benitez, J; Rivas, C; Bignon, YJ; Chang-Claude, J; Hamann, U; Cornelisse, CJ; Devilee, P; Beckmann, MW; Nestle-Kramling, C; Daly, PA; Haites, N; Varley, J; Lalloo, F; Evans, G; Maugard, C; Meijers-Heijboer, H; Klijn, JGM; Olah, E; Gusterson, BA; Pilotti, S; Radice, P; Scherneck, S; Sobol, H; Jacquemier, J; Wagner, T; Peto, J; Stratton, MR; McGuffog, L; Easton, DF; (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clinical cancer research , 11 (14). p. 5175. ISSN 1078-0432 DOI: 10.1158/1078-0432.CCR-04-2424

Full text not available from this repository.

Abstract

Purpose: To investigate the proportion of breast cancers arising inpatients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. Experimental Design: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. Results: All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus 12%; CK5/6: 58% versus 7%; CK17: 53% versus 10%; osteonectin: 43% versus 19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. Conclusion: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
PubMed ID: 16033833
Web of Science ID: 230529800017
URI: http://researchonline.lshtm.ac.uk/id/eprint/13302

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
255Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item